As it is already available in clinics with the anti-VEGF Bevacizumab that targets angiogenesis and thus the metastatic niche of colorectal liver metastases, some of the identified genes may offer opportunities to remodel the tumor environment, increase chemotherapy efficiency and improve patient survival in CRC. This evidence concerns the gene VEGFA and neoplasm.